Avania’s Post

We're thrilled to have successfully managed another Post-market Medical Device study! After taking over from another CRO, our team resolved previously identified issues to ensure compliance and achieve targeted study timelines. Read the full case study here: https://lnkd.in/eEv9rmE9 #Clinicology #CRO #ClinicalTrials #MedicalDeviceStudy

Curious about the journey from regulatory approval to pivotal progress in clinical trials? Discover the essential steps that pave the way for groundbreaking medical advancements. #ClinicalTrials #MedicalResearch #HealthcareInnovation #Clinicaltrialsinpakistan #CRO #IBBPS

🌟 Exciting times in #MedicalDevices! Sequana Medical's alfapump breakthrough for #LiverCirrhosis treatment, is up for #FDA review. Over a decade of success in Europe and promising results from the POSEIDON study could change #AscitesManagement. FDA decision expected in 2024 🏥💡. Learn more Sam O'Leary Nathan Read Nathan Upton Jowell Grandison Alan Ling

Choosing a CRO is a big decision. There are a lot of factors to consider. But don't worry, we've got you covered. Read our blog to learn more about the key considerations and how to make the best choice for your clinical trials. https://lnkd.in/eaQ8vUna #clinicaltrial #CRO #retina

SynchroMed III Infusion System - Now CE Mark approved: I am proud to be part of a company that is at the helm of developing proven, cutting-edge engineering, research, clinical experience, and collaboration: The newly CE Mark approved Synchromed III™ Infusion System (CE0123). Offering patients suffering from cancer pain, chronic pain and severe spasticity, an opportunity to manage their symptoms with fewer side effects.1-6 The Synchromed III™ takes the best-in-class drug delivery platform a step further with enhanced reliability, robust cybersecurity, and an upgradable platform. The SynchroMed III™ system will be commercially available in Europe in 2024. #SynchroMedIII #TargetedDrugDelivery #MDTPainIntervention #SevereSpasticity 1. Hamza, M. et al. Prospective Study of 3-Year Follow-Up of Low-Dose Intrathecal Opioids in the Management of Chronic Nonmalignant Pain. Pain Medicine (United States) 13, 1304–1313 (2012). 2. Smith, T. J. et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. Journal of Clinical Oncology 20, 4040–4049 (2002). 3. Pope, J. E., Deer, T. R., Amirdelfan, K., McRoberts, W. P. & Azeem, N. The pharmacology of spinal opioids and ziconotide for the treatment of non-cancer pain. Current Neuropharmacology 15, 206–216 (2017). 4. Meythaler, J., Guin-Renfroe, S., Brunner, R. & Hadley, M. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 32, 2099–109 (2001). 5. Gilmartin, R. et al. Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial. Journal of Child Neurology 15, 71–77 (2000). 6. Ivanhoe, C. B., Francisco, G. E., McGuire, J. R., Subramanian, T. & Grissom, S. P. Intrathecal Baclofen Management of Poststroke Spastic Hypertonia: Implications for Function and Quality of Life. Archives of Physical Medicine and Rehabilitation 87, 1509–1515 (2006). #MedtronicEmployee #MedtronicEmployee

Today we celebrate all that has been accomplished thanks to clinical trials and the people behind them. Happy clinical trials day to all fellow trailblazers (or should we say trialblazers 😉) in clinical research! #ClinicalTrialsDay #CTD2024 #medicaldevices #expert #CRO #humanhealth #archerresearch

A clinical symphony of Sponsors, CROs, Sites, and Participants for medical advancements #clinicalresearch #clinicaltrials #clinicalresearchassociate #clinicaldevelopment #medicaladvancements #cro #researchanddevelopment #stakeholders #research #goodclinicalpractice #aiinhealthcare

Next stop on NEB's 50-stop world tour: 📍London! Excited to be exhibiting at Advanced Therapies 2024 next week. Stop by booth 21 to chat with NEB, learn more about our GMP capabilities and how we can support you at different stages of your ATMPs pipeline. @Marc Davis, @Chris Lounds, @Laura Wood, @Euan Forbes Ph.D #mRNA #RNA #Therapeutics #NEBturns50 #AdTherapies24 #CellTherapy #GeneTherapy"

In the latest from the criterium blog, we look at the importance of clinical trials. https://lnkd.in/eXBa7mcz #clinicaltrials #CRO

𝐅𝐢𝐧𝐝 𝐖𝐡𝐲 𝐅𝐃𝐀 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐲 𝐂𝐨𝐦𝐦𝐢𝐭𝐭𝐞𝐞 𝐯𝐨𝐭𝐞𝐝 𝐢𝐧 𝐟𝐚𝐯𝐨𝐫 𝐨𝐟 𝐀𝐁𝐁𝐎𝐓𝐓 Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the U.S. Food and Drug Administration (FDA) confirmed 13 to 1, with 0 abstention that the benefits of Abbott’s TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people with tricuspid regurgitation (TR). The panel’s decision was based on clinical data from the TRILUMINATE™ pivotal trial, as well as expert testimony. The panel’s vote will be considered by the #FDA when deciding on the approval of #triclip, a first-of-its-kind minimally invasive device specifically designed to treat the difficult-to-access tricuspid valve. Read More: https://lnkd.in/dzDrsr5B TriClip is approved for use in more than 50 countries, including in Europe and Canada, and has already been used to treat more than 10,000 people with TR. It is an investigational device in the United States. #mededgemea #MedicalAdvancements #MedicalInnovation #futuretech #healthcareinnovation #Abbott